Cargando…

Invariant NKT cells dictate antitumor immunity elicited by a bispecific antibody cotargeting CD3 and BCMA

CD3-engaging bispecific antibodies (BsAbs) have emerged as powerful therapeutic approaches by their ability to redirect T cells to eliminate tumor cells in a major histocompatibility complex–independent manner. However, how we can potentiate the efficacy of BsAbs remains largely unknown. To address...

Descripción completa

Detalles Bibliográficos
Autores principales: Casey, Mika, Tu, Cui, Harrison, Simon J., Nakamura, Kyohei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631633/
https://www.ncbi.nlm.nih.gov/pubmed/35830292
http://dx.doi.org/10.1182/bloodadvances.2022008118